IADR Abstract Archives
Modified Twin Block Treatment and Class II Division 1 Malocclusion
Objectives: To evaluate Oral Health Related Quality of Life (OHRQoL), self-esteem, self-perception of aesthetic treatment need (IOTN-AC) and 3D soft tissue changes in subjects with Class II division 1 malocclusion (II/1M) treated with a Modified Twin Block (MTB) compared to controls.
To evaluate OHRQoL and self-perception of IOTN-AC in parent groups.
Methods: Sixty subjects (31 males; 29 females, mean age 12.6±1.0) with II/1M received MTB treatment (MTBG) and 47 subjects (22 males; 25 females, mean age 12.5±0.7) with II/1M awaiting treatment served as controls (CG). At baseline (T1) and following MTB treatment or recall (T2) subjects completed three questionnaires: OHRQoL (CPQ11-14), self-esteem (CHQ-CF45) and IOTN-AC. Subjects had a 3D facial image captured at rest. At T1 and T2, each subject’s parent completed two questionnaires: OHRQoL and IOTN-AC. Statistical analyses comprised ANOVA (between groups for OHRQoL, self-esteem, 3D soft tissue changes), paired t-tests (within groups), Bowker’s symmetry test and Fisher’s Exact test (IOTN-AC).
Results: Forty-two subjects completed MTB treatment and 35 untreated II/1M subjects were recalled. At T1, groups were similar in age and gender (p>0.05) but overjet in MTBG was slightly greater (p=0.0016). At T2, OHRQoL and self-perception IOTN-AC improved significantly in subjects and parents of the MTBG (both p<0.05) but subject’s self-esteem remained unchanged. In both groups, at both time-points, agreement was poor regarding subject and parent perception of subject’s OHRQoL with parents rating it worse. From T1 to T2, statistically significant 3D soft tissue changes occurred at Pogonion (MTBG: 4.26±1.64mm; CG 3.29±1.95mm; p<0.05), but differences between groups were not clinically significant.
Conclusions: MTB treatment significantly improved OHRQoL and self-perception of IOTN-AC in subjects with II/1M and parents compared to controls.
Both groups had poor agreement between subject and parent perception of OHRQoL and IOTN-AC.
Treatment had no significant impact on subject’s self-esteem or soft tissue changes.
To evaluate OHRQoL and self-perception of IOTN-AC in parent groups.
Methods: Sixty subjects (31 males; 29 females, mean age 12.6±1.0) with II/1M received MTB treatment (MTBG) and 47 subjects (22 males; 25 females, mean age 12.5±0.7) with II/1M awaiting treatment served as controls (CG). At baseline (T1) and following MTB treatment or recall (T2) subjects completed three questionnaires: OHRQoL (CPQ11-14), self-esteem (CHQ-CF45) and IOTN-AC. Subjects had a 3D facial image captured at rest. At T1 and T2, each subject’s parent completed two questionnaires: OHRQoL and IOTN-AC. Statistical analyses comprised ANOVA (between groups for OHRQoL, self-esteem, 3D soft tissue changes), paired t-tests (within groups), Bowker’s symmetry test and Fisher’s Exact test (IOTN-AC).
Results: Forty-two subjects completed MTB treatment and 35 untreated II/1M subjects were recalled. At T1, groups were similar in age and gender (p>0.05) but overjet in MTBG was slightly greater (p=0.0016). At T2, OHRQoL and self-perception IOTN-AC improved significantly in subjects and parents of the MTBG (both p<0.05) but subject’s self-esteem remained unchanged. In both groups, at both time-points, agreement was poor regarding subject and parent perception of subject’s OHRQoL with parents rating it worse. From T1 to T2, statistically significant 3D soft tissue changes occurred at Pogonion (MTBG: 4.26±1.64mm; CG 3.29±1.95mm; p<0.05), but differences between groups were not clinically significant.
Conclusions: MTB treatment significantly improved OHRQoL and self-perception of IOTN-AC in subjects with II/1M and parents compared to controls.
Both groups had poor agreement between subject and parent perception of OHRQoL and IOTN-AC.
Treatment had no significant impact on subject’s self-esteem or soft tissue changes.